ClinicalTrials.gg
CompletedNCT01830543PIONEER AF-PCIUpdated Sep 19, 2017Results posted

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

A Phase 3 interventional study of rivaroxaban 2.5 mg and rivaroxaban 15 mg in Atrial Fibrillation and Percutaneous Coronary Intervention, sponsored by Janssen Scientific Affairs, LLC. Completed at 356 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-19.

Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.

Enrollment
10th of 45
2,124 · median 150
Started
2013
with 3 others
Phase 3
16 of 45
none open now
Registered
10th of 45
by date
Lead sponsor
2 of 45
Janssen Scientific Affairs, LLC

Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 10th largest by enrollment, is one of 4 that started in 2013, is one of 16 in phase 3, and was the 10th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing rivaroxaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel (or prasugrel or ticagrelor).

Read the detailed description

This is an open-label (both physician and participant know the treatment that the participant receives), randomized (study medication is assigned by chance), multicenter clinical study assessing the safety of 2 rivaroxaban treatment strategies and one vitamin K antagonist (VKA) treatment strategy in participants, who have paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF) and have had a percutaneous coronary intervention (PCI) with stent placement.

A target of 2,100 participants will be randomized into the study, with approximately 700 participants in each treatment strategy group. The randomization will be stratified by the intended duration of DAPT (1, 6, or 12 months).

The study consists of a screening phase, a 12-month open-label treatment phase, and an end-of-treatment/early withdrawal visit. The total duration of participation in the study for each participant is approximately 12 months.

03

Conditions studied

  • Atrial Fibrillation
  • Percutaneous Coronary Intervention

Keywords

  • Atrial Fibrillation
  • Irregular heart beat
  • rivaroxaban
  • aspirin
  • clopidogrel
  • prasugrel
  • ticagrelor
  • vitamin K antagonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a documented medical history of paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF)
  • Have undergone percutaneous coronary intervention (PCI) procedure (with stent placement) for primary atherosclerotic disease
  • Must have an (INR) of 2.5 or below to be randomized
  • Women must be before entry or practicing a highly effective method of when heterosexually active
  • Be willing and able to adhere to the prohibitions and restrictions specified in the study protocol

Exclusion criteria

Exclusion Criteria:

  • Have any condition that contraindicates anticoagulant or antiplatelet therapy or would have an unacceptable risk of bleeding, such as, but not limited to: count \<90,000/microliter at screening, history of intracranial hemorrhage, 12 month history of gastrointestinal bleeding, non-VKA induced elevated (PT) at screening
  • Have anemia of unknown cause with a level \<10 g/dL (\<6.21 mmol/L)
  • Have a history of stroke or (TIA)
  • Have a calculated (CrCl) \<30 mL/min at screening
  • Have known significant liver disease or liver function test (LFT) abnormalities
  • Have any severe condition that would limit to less than 12 months
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,124 participants (actual)

Study arms

  • Experimental
    rivaroxaban 2.5 mg twice daily

    rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months

    Drug: rivaroxaban 2.5 mg · Drug: rivaroxaban 15 mg · Drug: rivaroxaban 10 mg · Drug: aspirin (ASA) · Drug: clopidogrel · Drug: prasugrel · Drug: ticagrelor

  • Experimental
    vitamin K antagonist (VKA)

    dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months

    Drug: aspirin (ASA) · Drug: vitamin K antagonist (VKA) · Drug: clopidogrel · Drug: prasugrel · Drug: ticagrelor

  • Experimental
    rivaroxaban 15 mg once daily

    rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months

    Drug: rivaroxaban 15 mg · Drug: rivaroxaban 10 mg · Drug: clopidogrel · Drug: prasugrel · Drug: ticagrelor

Interventions

  • One 2.5 mg tablet twice daily for up to twelve months

  • One 15 mg tablet once daily for up to twelve months

  • One 10 mg tablet once daily for up to twelve months

  • Low-dose aspirin tablet once daily for twelve months

  • Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months

  • One 75 mg tablet once daily for up to twelve months

  • One 10 mg tablet once daily for up to twelve months

  • One 90 mg tablet twice daily for up to twelve months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinically Significant Bleeding

    Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (\>=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \>=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (\<) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \<15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.

    Time frame: Up to Month 12

Secondary outcomes

  1. Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding

    TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of \>= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \>=15 percent).

    Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12

  2. Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding

    TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to \<5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \<15 percent).

    Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12

  3. Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)

    A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.

    Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12

  4. Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)

    Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed.

    Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12

  5. Percentage of Participants With Cardiovascular Death

    The percentage of participants with the first occurrence of cardiovascular death were evaluated.

    Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12

  6. Percentage of Participants With Myocardial Infarction

    The percentage of participants with the first occurrence of Myocardial Infarction were evaluated.

    Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12

  7. Percentage of Participants With Stroke

    The percentage of participants with the first occurrence of Stroke were evaluated.

    Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12

  8. Percentage of Participants With Stent Thrombosis

    The percentage of participants with the first occurrence of stent thrombosis were evaluated.

    Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12

07

Results

Posted Jul 31, 2017
Limitations and caveats
First the stratification to either 1, 6 or 12 months of DAPT was based upon clinician choice and was not randomized. Secondly there was not sufficient power to definitively assess efficacy due to the modest number of adverse CV events.

Participant flow

Participant flow — Overall Study
MilestoneRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Started709709706
Treated696706697
Completed550557492
Not completed159152214
Withdrew: Subject decision192157
Withdrew: Adverse event917776
Withdrew: Death202222
Withdrew: Protocol violation377
Withdrew: Physician decision11512
Withdrew: Withdrawal by consent333
Withdrew: Other121737

Outcome measures

PrimaryPercentage of Participants With Clinically Significant Bleeding

Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (\>=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \>=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (\<) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \<15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.

Time frame:
Up to Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Bleeding
percentage of participantsRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Percentage of Participants With Clinically Significant Bleeding15.716.624.0
Statistical analysis
  • Rivaroxaban 15 mg vs Vitamin K Antagonist (VKA) · Log Rank · p = <0.001 · Hazard ratio (hr): 0.59 · 95% CI 0.47 to 0.76
  • Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) vs Vitamin K Antagonist (VKA) · Log Rank · p = <0.001 · Hazard ratio (hr): 0.63 · 95% CI 0.5 to 0.8
SecondaryPercentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding

TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of \>= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \>=15 percent).

Time frame:
Up to Month 12 and end of DAPT-Month 1, 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding
percentage of participantsRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Up to Month 12 (n= 696, 706, 697)2.01.72.9
End of DAPT-1 Month (n= 0, 108,113)NA0.94.4
End of DAPT-6 Month (n= 0, 248,243)NA2.83.7
End of DAPT-12 Month (n= 0, 350,341)NA1.11.8
Statistical analysis
  • Rivaroxaban 15 mg vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.234 · Hazard ratio (hr): 0.66 · 95% CI 0.33 to 1.31
  • Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.114 · Hazard ratio (hr): 0.57 · 95% CI 0.28 to 1.16
SecondaryPercentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding

TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to \<5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \<15 percent).

Time frame:
Up to Month 12 and end of DAPT-Month 1, 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding
percentage of participantsRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Up to Month 12 (n= 696, 706, 697)1.01.01.9
End of DAPT-1 Month (n= 0, 108, 113)NA0.91.8
End of DAPT-6 Month (n= 0, 248, 243)NA0.42.5
End of DAPT-12 Month (n= 0, 350, 341)NA1.41.5
Statistical analysis
  • Rivaroxaban 15 mg vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.144 · Hazard ratio (hr): 0.51 · 95% CI 0.2 to 1.28
  • Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.134 · Hazard ratio (hr): 0.5 · 95% CI 0.2 to 1.26
SecondaryPercentage of Participants With Bleeding Requiring Medical Attention (BRMA)

A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.

Time frame:
Up to Month 12 and end of DAPT-Month 1, 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)
percentage of participantsRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Up to Month 12 (n= 696, 706, 697)13.414.419.9
End of DAPT-1 Month (n= 0, 108, 113)NA16.718.6
End of DAPT-6 Month (n= 0, 248, 243)NA12.923
End of DAPT-12 Month (n= 0, 350, 341)NA14.918.2
Statistical analysis
  • Rivaroxaban 15 mg vs Vitamin K Antagonist (VKA) · Log Rank · p = <0.001 · Hazard ratio (hr): 0.61 · 95% CI 0.47 to 0.8
  • Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.002 · Hazard ratio (hr): 0.67 · 95% CI 0.52 to 0.86
SecondaryPercentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)

Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed.

Time frame:
Up to Month 12 and end of DAPT-Month 1, 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)
percentage of participantsRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Up to Month 12 (n= 694, 704, 695)5.95.15.2
End of DAPT-1 Month (n= 0, 108, 112)NA5.64.5
End of DAPT-6 Month (n= 0, 248, 243)NA6.53.7
End of DAPT-12 Month (n= 0, 348, 340)NA46.5
Statistical analysis
  • Rivaroxaban 15 mg vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.75 · Hazard ratio (hr): 1.08 · 95% CI 0.69 to 1.68
  • Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.765 · Hazard ratio (hr): 0.93 · 95% CI 0.59 to 1.48
SecondaryPercentage of Participants With Cardiovascular Death

The percentage of participants with the first occurrence of cardiovascular death were evaluated.

Time frame:
Up to Month 12 and end of DAPT-Month 1, 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Cardiovascular Death
percentage of participantsRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Up to Month 12 (n= 694, 704, 695)2.221.6
End of DAPT-1 Month (n= 0, 108, 112)NA1.91.8
End of DAPT-6 Month (n= 0, 248, 243)NA2.41.6
End of DAPT-12 Month (n= 0, 348, 340)NA1.71.5
Statistical analysis
  • Rivaroxaban 15 mg vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.523 · Hazard ratio (hr): 1.29 · 95% CI 0.59 to 2.8
  • Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.664 · Hazard ratio (hr): 1.19 · 95% CI 0.54 to 2.62
SecondaryPercentage of Participants With Myocardial Infarction

The percentage of participants with the first occurrence of Myocardial Infarction were evaluated.

Time frame:
Up to Month 12 and end of DAPT-Month 1, 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Myocardial Infarction
percentage of participantsRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Up to Month 12 (n= 694, 704, 695)2.72.43
End of DAPT-1 Month (n= 0, 108, 112)NA2.80.9
End of DAPT-6 Month (n= 0, 248, 243)NA2.82.5
End of DAPT-12 Month (n= 0, 348, 340)NA24.1
Statistical analysis
  • Rivaroxaban 15 mg vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.625 · Hazard ratio (hr): 0.86 · 95% CI 0.46 to 1.59
  • Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.374 · Hazard ratio (hr): 0.75 · 95% CI 0.4 to 1.42
SecondaryPercentage of Participants With Stroke

The percentage of participants with the first occurrence of Stroke were evaluated.

Time frame:
Up to Month 12 and end of DAPT-Month 1, 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Stroke
percentage of participantsRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Up to Month 12 (n= 694, 704, 695)1.21.41
End of DAPT-1 Month (n= 0, 108, 112)NA1.92.7
End of DAPT-6 Month (n= 0, 248, 243)NA2.40
End of DAPT-12 Month (n= 0, 348, 340)NA0.61.2
Statistical analysis
  • Rivaroxaban 15 mg vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.891 · Hazard ratio (hr): 1.07 · 95% CI 0.39 to 2.96
  • Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.53 · Hazard ratio (hr): 1.36 · 95% CI 0.52 to 3.58
SecondaryPercentage of Participants With Stent Thrombosis

The percentage of participants with the first occurrence of stent thrombosis were evaluated.

Time frame:
Up to Month 12 and end of DAPT-Month 1, 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Stent Thrombosis
percentage of participantsRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Up to Month 12 (n= 694, 704, 695)0.70.90.6
End of DAPT-1 Month (n= 0, 108, 112)NA1.90.9
End of DAPT-6 Month (n= 0, 248, 243)NA1.60.4
End of DAPT-12 Month (n= 0, 348, 340)NA00.6
Statistical analysis
  • Rivaroxaban 15 mg vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.79 · Hazard ratio (hr): 1.2 · 95% CI 0.32 to 4.45
  • Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) vs Vitamin K Antagonist (VKA) · Log Rank · p = 0.574 · Hazard ratio (hr): 1.44 · 95% CI 0.4 to 5.09

Adverse events

Collected over Upto 12 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban 15 mg—237/696 (34.1%)174/696 (25%)
Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)—225/706 (31.9%)210/706 (29.7%)
Vitamin K Antagonist (VKA)—271/697 (38.9%)234/697 (33.6%)
Most frequent serious events
Showing 10 of 397
Most frequent serious events
EventRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
Cardiac FailureCardiac disorders21/69616/70631/697
Angina UnstableCardiac disorders16/69612/70623/697
Atrial FibrillationCardiac disorders13/69621/70623/697
Angina PectorisCardiac disorders7/69613/70615/697
PneumoniaInfections and infestations12/69612/70614/697
Cardiac Failure CongestiveCardiac disorders7/6964/70611/697
DyspnoeaRespiratory, thoracic and mediastinal disorders6/6966/70610/697
Gastrointestinal HaemorrhageGastrointestinal disorders7/6967/7069/697
Chest PainGeneral disorders8/6964/7069/697
SyncopeNervous system disorders1/6964/7068/697
Most frequent other events
Showing 10 of 13
Most frequent other events
EventRivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)
EpistaxisRespiratory, thoracic and mediastinal disorders67/69659/70682/697
HaematomaVascular disorders21/69631/70661/697
ContusionInjury, poisoning and procedural complications13/69635/70625/697
DyspnoeaRespiratory, thoracic and mediastinal disorders27/69621/70618/697
HaematuriaRenal and urinary disorders18/69614/70614/697
Gingival BleedingGastrointestinal disorders17/69616/70618/697
Oedema PeripheralGeneral disorders14/69612/70618/697
Angina PectorisCardiac disorders13/69618/70612/697
DiarrhoeaGastrointestinal disorders12/69618/70611/697
HypertensionVascular disorders17/6962/7067/697

Baseline characteristics

The intent-to-treat analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)Rivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)Total
Mean70.4 ± 9.1270 ± 9.1169.9 ± 8.6770.1 ± 8.97
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)Total
Female181174188543
Male5285355181581
Region of Enrollment
Region of Enrollment(participants)Rivaroxaban 15 mgRivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)Vitamin K Antagonist (VKA)Total
Argentina32272382
Australia37515
Belgium14182052
Brazil14141341
Bulgaria678074221
Canada23241966
Chile57618
Czech Republic1791440
Denmark22812
France33262584
Germany9698101295
Italy26262072
Korea, Republic of11111739
Malaysia15511
Mexico73313
Netherlands24172768
Poland717869218
Romania15161950
Russian Federation908689265
Sweden15141847
Taiwan, Province of China88925
Turkey11141843
Ukraine19241760
United Kingdom484439131
United States564946151
South Africa1225
08

Study locations

356 sites
  • Huntsville, Alabama, United States
  • Los Alamitos, California, United States
  • Mission Viejo, California, United States
  • Oceanside, California, United States
  • Riverside, California, United States
  • Sacramento, California, United States
  • San Francisco, California, United States
  • Stockton, California, United States
  • Thousand Oaks, California, United States
  • Torrance, California, United States
  • Colorado Springs, Colorado, United States
  • Lakewood, Colorado, United States
  • Littleton, Colorado, United States
  • Danbury, Connecticut, United States
  • Washington, D.C., District of Columbia, United States
  • Atlantis, Florida, United States
  • Clearwater, Florida, United States
  • Daytona Beach, Florida, United States
  • Jacksonville, Florida, United States
  • Port Charlotte, Florida, United States
  • Safety Harbor, Florida, United States
  • Saint Petersburg, Florida, United States
  • Tallahassee, Florida, United States
  • Tampa, Florida, United States
  • Columbus, Georgia, United States
  • Macon, Georgia, United States
  • Marietta, Georgia, United States
  • Boise, Idaho, United States
  • Hazel Crest, Illinois, United States
  • Indianapolis, Indiana, United States
  • Munster, Indiana, United States
  • Hammond, Louisiana, United States
  • Lake Charles, Louisiana, United States
  • Slidell, Louisiana, United States
  • Auburn, Maine, United States
  • Bangor, Maine, United States
  • Baltimore, Maryland, United States
  • Detroit, Michigan, United States
  • Lansing, Michigan, United States
  • Mount Clemens, Michigan, United States
  • Petoskey, Michigan, United States
  • Ypsilanti, Michigan, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Kalispell, Montana, United States
  • Las Vegas, Nevada, United States
  • Hackensack, New Jersey, United States
  • Haddon Heights, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Newark, New Jersey, United States
  • Ridgewood, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • New York, New York, United States
  • Peekskill, New York, United States
  • Sanford, North Carolina, United States
  • Bartlesville, Oklahoma, United States
  • Oklahoma City, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Bend, Oregon, United States
  • Portland, Oregon, United States
  • Abington, Pennsylvania, United States
  • Camp Hill, Pennsylvania, United States
  • Doylestown, Pennsylvania, United States
  • Erie, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Sayre, Pennsylvania, United States
  • York, Pennsylvania, United States
  • Greenville, South Carolina, United States
  • Mount Pleasant, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Jackson, Tennessee, United States
  • Knoxville, Tennessee, United States
  • Austin, Texas, United States
  • Fort Worth, Texas, United States
  • Humble, Texas, United States
  • Odessa, Texas, United States
  • Plano, Texas, United States
  • Layton, Utah, United States
  • Charlottesville, Virginia, United States
  • Manassas, Virginia, United States
  • Midlothian, Virginia, United States
  • Richmond, Virginia, United States
  • Bellevue, Washington, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Weston, Wisconsin, United States
  • Bahia Blanca, Argentina
  • Buenos Aires, Argentina
  • C.a.b.a., Argentina
  • Cordoba, Argentina
  • Corrientes, Argentina
  • La Plata, Argentina
  • Resistencia, Argentina
  • Rosario, Argentina
  • Santa Fe, Argentina
  • Vicente Lopez, Argentina
  • Chermside N/A, Australia
  • Epping, Australia
  • Hobart, Australia
  • Kogarah, Australia

Showing the first 100 of 356 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. Circ Cardiovasc Interv. 2019 Nov;12(11):e008160. doi: 10.1161/CIRCINTERVENTIONS.119.008160. Epub 2019 Nov 11. PubMed 31707805 ↗
  • Gibson WJ, Nafee T, Travis R, Yee M, Kerneis M, Ohman M, Gibson CM. Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. J Thromb Thrombolysis. 2020 Jan;49(1):1-9. doi: 10.1007/s11239-019-01940-8. PubMed 31535314 ↗
  • Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 Feb;12(2):e007124. doi: 10.1161/CIRCINTERVENTIONS.118.007124. PubMed 30704287 ↗
  • Chi G, Kerneis M, Kalayci A, Liu Y, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. Am Heart J. 2018 Sep;203:17-24. doi: 10.1016/j.ahj.2018.06.003. Epub 2018 Jun 13. PubMed 30015064 ↗
  • Chi G, Yee MK, Kalayci A, Kerneis M, AlKhalfan F, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. J Thromb Thrombolysis. 2018 Oct;46(3):346-350. doi: 10.1007/s11239-018-1703-5. PubMed 29943350 ↗
  • Kerneis M, Gibson CM, Chi G, Mehran R, AlKhalfan F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, Nafee T, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Fox KAA, Cohen M. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. JACC Cardiovasc Interv. 2018 Apr 9;11(7):626-634. doi: 10.1016/j.jcin.2017.11.009. Epub 2018 Mar 14. PubMed 29550085 ↗
  • Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016 Dec 22;375(25):2423-2434. doi: 10.1056/NEJMoa1611594. Epub 2016 Nov 14. PubMed 27959713 ↗
  • Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GY, Cohen M, Peterson ED, Fox KA. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 2017 Jan 24;135(4):323-333. doi: 10.1161/CIRCULATIONAHA.116.025783. Epub 2016 Nov 14. Erratum In: Circulation. 2017 Mar 21;135(12):e789. doi: 10.1161/CIR.0000000000000495. PubMed 27881555 ↗
  • Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015 Apr;169(4):472-8.e5. doi: 10.1016/j.ahj.2014.12.006. Epub 2014 Dec 20. PubMed 25819853 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Jul 2016, 38 months.

Results were first posted in Jul 2017, 1 year after primary completion.

Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 38 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2013
First posted
Apr 12, 2013
StartActual
May 10, 2013
Primary completionActual
Jul 28, 2016
CompletionActual
Jul 28, 2016
Results first posted
Jul 31, 2017
Last update
Sep 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01830543
Collaborators
Bayer
Responsible party
Sponsor
First posted
Apr 12, 2013
Start date
May 10, 2013
Primary completion
Jul 28, 2016
Completion
Jul 28, 2016
Results posted
Jul 31, 2017
Last update
Sep 19, 2017

Study contacts

Janssen Scientific Affairs, LLC Clinical Trial
study director · Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rivaroxaban · Aspirin · Vitamin K Antagonist

Start the discussion